Annual report pursuant to Section 13 and 15(d)

Royalty Liability

Royalty Liability
12 Months Ended
Dec. 31, 2015
Royalty Liability [Abstract]  
Royalty Liability [Text Block]
8. Royalty Liability
On March 28, 2013, we amended the agreements with Deerfield terminating our option to repurchase the royalty rights. As a result, we recognized a gain on the extinguishment of the royalty liability of approximately $9.0 million, which was recorded in other income, because we are no longer required to account for it as a liability. Additionally, we will no longer recognize royalty income related to the Fanapt royalty payments received from Novartis unless Fanapt sales exceed certain thresholds.